Pharmacological interventions for peripheral artery disease

Bibliography

• Hirsch AT, CRIQUI MH, TREAT-JACOBSEN D et al.: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA (2001) 286:1317-1324.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, RUTHERFORD RB: TASC Working Group. Management of peripheral arterial disease (PAD). J. Vasc. Surg. (2000) 31:S1-S296.
   Google Scholar
• BEEBE HG: Intermittent claudication: effective medical management of a common circulatory program. Am. J. Cardiol. (2001) 87(Suppl.):D14-D18.
   PubMed Web of Science ®Google Scholar
• HOOI JD, KESTER AD, STOFFERS HE, OVERDIJK MM, VAN REE JW, KNOTTNERUS JA: Incidence of and risk factors for asymptomatic peripheral arterial disease: a longitudinal study. Am. J. Epidemiol. (2001) 153:666-672.
   PubMed Web of Science ®Google Scholar
• FOWKES FG, HOUSLEY E, CAWOOD EH, MACINTYRE CC, RUCKLEY CV, PRESCOTT RU: Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int. J. Epidemiol. (1991) 20:384-392.
   PubMed Web of Science ®Google Scholar
• CLEMENT DL, DE BUYZERE ML, DUPREZ DA: Hypertension in peripheral arterial disease. Curr. Pharm. Des. (2004) 10:3615-3620.
   PubMedGoogle Scholar
• MEIJER WT, HOES AW, RUTGERS D, BOTS ML, HOFMAN A, GROBBEE DE: Peripheral arterial disease in the elderly: the Rotterdam study. Arterioscler. Thromb. Vasc. Biol. (1998) 18:185-192.
   PubMed Web of Science ®Google Scholar
• AMERICAN Diabetes Association: Peripheral arterial disease in people with diabetes. Diabetes Care (2003) 26:3333-3341.
   Google Scholar
• HIATT WR, HOAG S, HAMMAN RF: Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. Circulation (1995) 91:1472-1479.
   PubMed Web of Science ®Google Scholar
• ROTHWELL PM, COULL AJ, SILVER LE et al.: Population-based study of event rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet (2005) 366:1773-1783.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT MM, MEHTA S, LIU K et al.: Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J. Gen. Intern. Med. (1999) 14:173-181.
   PubMedGoogle Scholar
• DUPREZ D: Natural history and evolution of peripheral obstructive arterial disease. Int. Angiol. (1992) 11:165-168.
   PubMed Web of Science ®Google Scholar
• HERTZER NR, BEVEN EG, YOUNG JR et al.: Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann. Surg. (1984) 199:223-233.
   PubMed Web of Science ®Google Scholar
• DORMANDY J MAHIR M, ASCADY G, et al.: Fate of the patient with chronic leg ischaemia. A review article. J. Cardiovasc. Surg. (1989) 30:50-57.
   PubMed Web of Science ®Google Scholar
• ARONOW WS, AHN C: Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥ 62 years of age. Am. J. Cardiol. (1994) 74:64-65.
   PubMed Web of Science ®Google Scholar
• BHATT DL, STEG PG, OHMAN EM et al.: REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 295:180-189.
   PubMed Web of Science ®Google Scholar
• DUPREZ D, CLEMENT DL: Medical treatment of peripheral vascular disease: good or bad? Eur. Heart J. (1992) 13:149-151.
   PubMedGoogle Scholar
• HIRSCH AT, HASKAL ZJ, HERTZER NR et al.: ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease). J. Am. Coll. Cardiol. (2006) 47:1239-1312.
   PubMed Web of Science ®Google Scholar
• TASC Force Writing Group: Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int. Angiol. (2000) 19(1 Suppl. 1):I-XXIV,1-304.
   Google Scholar
• KANNEL WB, SHURTLEFF D: The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics (1973) 28:61-68.
   PubMed Web of Science ®Google Scholar
• LAW M, TANG JL: An analysis of the effectiveness of interventions intended to help people stop smoking. Arch. Intern. Med. (1995) 155:1933-1941.
   PubMed Web of Science ®Google Scholar
• JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation, N. Engl. J. Med. (1999) 340:685–691.
   PubMed Web of Science ®Google Scholar
• TURNBULL F; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet (2003) 362:1527-1535.
   Google Scholar
• LIP GY, MAKIN AJ: Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst. Rev. (2003) (4):CD003075.
   Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288:2981-2997.
   Google Scholar
• FROHLICH ED, TARAZI RC, DUSTAN HP: Peripheral arterial insufficiency: a complication of beta-adrenergic blocking therapy. JAMA (1969) 208:2471-2472.
   PubMed Web of Science ®Google Scholar
• SOLOMON SA, RAMSAY LE, YEO WW, PARNELL L, MORRIS-JONES W: β blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ (1991) 303:1100-1104.
   PubMed Web of Science ®Google Scholar
• RADACK K, DECK C: β-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch. Intern. Med. (1991) 151:1769-1776.
   PubMed Web of Science ®Google Scholar
• POLDERMANS D, BOERSMA E, BAX JJ et al.: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N. Engl. J. Med. (1999) 341:1789-1794.
   PubMed Web of Science ®Google Scholar
• HIRSCH AT, DUPREZ D: The potential role of angiotensin converting enzyme inhibition in peripheral arterial disease. Vasc. Med. (2004) 9:1-6.
   PubMedGoogle Scholar
• SONECHA TN , NICOLAIDES AN, KYPRIANOU P et al.: The effect of enalapril of leg muscle blood flow in patients with claudication. Inter. Angio. (1990) 9:22-24.
   PubMedGoogle Scholar
• BERNARDI D, BARTOLI P, FERERI A, GERI AB, IERI A: Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound. Angiology (1988) 39:942-952.
   PubMedGoogle Scholar
• ROBERTS DH, TSAO Y, LINGE K, MCLOUGHLIN GA, BRECKENBRIDGE A: Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology (1992) 43:748-756.
   PubMedGoogle Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G; Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. (2000) 342:145-153.
   PubMed Web of Science ®Google Scholar
• MEHLER PS, COLL JR, ESTACIA R, ESLER A, SCHRIER RW, HIATT WR: Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation (2003) 107:753-756.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, BOND MG, HENNIG M et al.: European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation (2002) 106:2422-2427.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, FAGARD R, THIJS L et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 350:757-764.
   PubMed Web of Science ®Google Scholar
• FOWKES FG, HOUSLY E, RIEMERSMA RA et al.: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am. J. Epidemiol. (1992) 135:331-340.
   PubMed Web of Science ®Google Scholar
• POMREHN P, DUNCAN B, WEISSFELD L et al.: The association of dyslipoproteinemia with symptoms and signs of peripheral arterial disease: the lipids research clinics program prevalence study. Circulation (1986) 73(Suppl. I):I100-I107.
   PubMed Web of Science ®Google Scholar
• DREXEL H, STEURER J, MUNTWYLER J et al.: Predictors of the presence and extent of peripheral arterial occlusive disease. Circulation (1996) 94 (Suppl. II):II199-II205.
   PubMedGoogle Scholar
• VALENTINE JR, GRAYBURN PA, VEGA GL, GRUDY M: Lp(a) lipoprotein is an independent, discriminating risk factor for premature atherosclerosis among white men. Arch. Intern. Med. (1994) 154:801-806.
   PubMed Web of Science ®Google Scholar
• MORENO PR, FUSTER V: The year in atherothrombosis. J. Am. Coll. Cardiol. (2004) 44:2099-2110.
   PubMedGoogle Scholar
• Heart Protection Study Collaborative Group: Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. (2007) 45:645-654.
   Google Scholar
• PEDERSEN TR, KJEKSHUS J, PYÖRÄLÄ K et al.: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am. J. Cardiol. (1998) 81:333-335.
   PubMed Web of Science ®Google Scholar
• SCHILLINGER M, EXNER M, MLEKUSCH M et al.: Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur. Heart J. (2004) 25:742-748.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT MM, GURALNIK JM, GREENLAND P et al.: Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation (2003) 107:757-761.
   PubMed Web of Science ®Google Scholar
• MONDILLO S, BALLO P, BARBATI R et al.: Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am. J. Med. (2003) 114:359-364.
   PubMed Web of Science ®Google Scholar
• ARONOW WS, NAYAK D, WOODWORTH S, AHN C: Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am. J. Cardiol. (2003) 92:711-712.
   PubMed Web of Science ®Google Scholar
• MOHLER ER, HIATT WR, CREAGER MA: Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation (2003) 108:1481-1486.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, MC GEE DL: Diabetes and cardiovascular disease. The Framingham Study. JAMA (1979) 241:2035-2038.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet (1998) 352:837-853.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet (1998) 352:854-865.
   Google Scholar
• The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am. J. Cardiol. (1995) 75:894-903.
   Google Scholar
• American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care (2003) 26(Suppl. 1):S33-S50.
   Google Scholar
• Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324:71-86.
   Google Scholar
• DORFFLER-Melly J, ADAM DJ, BULLER HR, KOOPMAN MM, PRINS MH: Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst. Rev. (2003) (3):CD000535.
   Google Scholar
• PATRONO C, GARCIA RODRIGUEZ LA, LANDOLFI R, BAIGENT C: Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. (2005) 353:2373-2383.
   PubMed Web of Science ®Google Scholar
• HESS H, MIETASCHIK A, DEICHSEL G: Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet (1985) 1:415-419.
   PubMed Web of Science ®Google Scholar
• GOLDHABER SZ, MANSON JE, STAMPFER MJ et al.: Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study. Lancet (1992) 340:143-145.
   PubMed Web of Science ®Google Scholar
• JANZON L, BERGQVIST D, BOBERG J et al.: Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicenter Study. J. Intern. Med. (1990) 227:301-308.
   PubMed Web of Science ®Google Scholar
• BALSANO F, COCCHERI S, LIBRETTI A et al.: Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J. Lab. Clin. Med. (1989) 114:84-91.
   PubMedGoogle Scholar
• BERGQVIST D, ALMGREN B, DICKINSON JP: Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur. J. Vasc. Endovasc. Surg. (1995) 10:69-76.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, WEINBERG PD, ROZENBERG-BEN-DROR K, YARNOLD PR, KWAAN HC, GREEN D: Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann. Intern. Med. (1998) 128:541-544.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ, SUDLOW CL, DUNBABIN DW: Thienopyridine derivates (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst. Rev. (2000) 2:CD001246.
   Google Scholar
• Caprie Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329-1339.
   Google Scholar
• BENNETT CL, CONNORS JM, CARWILE JM et al.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med. (2000) 342:1773-1777.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, FOX KAA, HACKE W et al.; for the CHARISMA Investigators: clopidogrel and aspirin vs aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. (2006) 354:1706-1717.
   PubMed Web of Science ®Google Scholar
• BALSANO F, VIOLI F: Effect of picotamide on the clinical progression of peripheral vascular disease: a double-blind placebo-controlled study. Circulation (1993) 87:1563-1569.
   PubMedGoogle Scholar
• Prevention of atherosclerotic complications: controlled trial of ketanserin. BMJ (1989) 298:424-430.
   PubMed Web of Science ®Google Scholar
• WAVE Investigators: The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am. Heart J. (2006) 151:1-9.
   PubMed Web of Science ®Google Scholar
• GRAHAM IM, DALY LE, REFSUM HM et al.: Plasma homocysteine as a risk for vascular disease: the European Concerted Action Project. JAMA (1997) 227:1775-1781.
   Google Scholar
• CLARKE R, DALY L, ROBINSON K et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. (1991) 324:1149-1155.
   PubMed Web of Science ®Google Scholar
• ABBAS R, CHOW CP, BROWDER NJ et al.: In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms. Hum. Exp. Toxicol. (2000) 19:178-184.
   PubMed Web of Science ®Google Scholar
• KOHDA N, TANI T, NAKAYAMA S et al.: Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb. Res. (1999) 96:261-268.
   PubMed Web of Science ®Google Scholar
• IGAWA T, TANI T, CHIJIWA T et al.: Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb. Res. (1990) 57:617-623.
   PubMed Web of Science ®Google Scholar
• MONEY SR, HERD JA, ISAACSOHN JL et al.: Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J. Vasc. Surg. (1998) 27:267-274.
   PubMed Web of Science ®Google Scholar
• DAWSON DL, CUTLER BS, MESSNER MH, STRANDNESS DEJ: Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter randomised, prospective, double-blind trial. Circulation (1998) 98:678-686.
   PubMed Web of Science ®Google Scholar
• BEEBE HG, DAWSON DL, CUTLER BS et al.: A new pharmacological treatment for intermittent claudication: results of a randomised, multicenter trial. Arch. Intern. Med. (1999) 159:2041-2050.
   PubMed Web of Science ®Google Scholar
• STRANDNESS DE JR, DALMAN RL, PANIAN S et al.: Effect of cilastozol in patients with intermittent claudication: a randomised, double-blind, placebo-controlled study. Vasc. Endovasc. Surg. (2002) 36:83-91.
   PubMedGoogle Scholar
• DAWSON DL, CUTLER BS, HIATT WR et al.: A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med. (2000) 109:523-530.
   PubMed Web of Science ®Google Scholar
• REGENSTEINER JG, WARE JE JR, MCCARTHY WJ et al.: Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease meta-analysis of six randomized controlled trials. J. Am. Geriatr. Soc. (2002) 50:1939-1946.
   PubMed Web of Science ®Google Scholar
• MOHLER ER III, BEEBE HG, SALLES-CUHNA S et al.: Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc. Med. (2001) 6:151-156.
   PubMed Web of Science ®Google Scholar
• SAMKASKA CP, WINFIELD EA: Pentoxifylline. J. Am. Acad. Dermatol. (1994) 30:603-621.
   PubMed Web of Science ®Google Scholar
• PORTER JM, CUTLER BS, LEE BY et al.: Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. (1982) 104:66-72.
   PubMed Web of Science ®Google Scholar
• LINDGARDE F, JELNES R, BJORKMAN H et al.: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation (1989) 80:1549-1556.
   PubMed Web of Science ®Google Scholar
• GIROLAMI B, BERNARDI E, PRINS MH et al.: Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline or naftidrofuryl: a meta-analysis. Arch. Intern. Med. (1999) 159:337-345.
   PubMed Web of Science ®Google Scholar
• HOOD SC, MOHER D, BARBER GG: Management of intermittent claudication with pentoxifylline: meta-analysis of randomised controlled trials. CMAJ (1996) 155:1053-1059.
   PubMed Web of Science ®Google Scholar
• ERNST E.: Pentoxifylline for intermittent claudication: a critical review. Angiology (1994) 45:339-345.
   PubMed Web of Science ®Google Scholar
• LEHERT P, COMTE S, GAMAND S, BROWN TM: Naftidrofuryl in intermittent claudication: a retrospective analysis. J. Cardiovasc. Pharmacol. (1994) 23(Suppl. 3):S48-S52.
   PubMedGoogle Scholar
• MOODY AP, AL-KHAFFAF HS, LEHERT P, HARRIS PL, CHARLESWORTH D: An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J. Cardiovasc. Pharmacol. (1994) 23(Suppl. 3):S44-S47.
   PubMed Web of Science ®Google Scholar
• TRUBESTEIN G, BOKME H, HEIDRICH H et al.: Naftidrofuryl in chronic arterial disease: results of a controlled multicenter study. Angiology (1994) 35:701-708.
   Google Scholar
• ADHOUTE G, ANDREASSIAN B, BOCCALON H et al.: Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J. Cardiovasc. Pharmacol. (1990) 16(Suppl. 3):S75-S80.
   PubMed Web of Science ®Google Scholar
• ADHOUTE G, BACOURT F, BARRAL M et al.: Naftidrofuryl in chronic arterial disease: results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology (1986) 37:160-169.
   PubMed Web of Science ®Google Scholar
• KRIESSMANN A, NEIS A: Demonstration of the clinical effectiveness of naftidrofuryl in intermittent claudication. VASA (1988) 24:27-32.
   PubMedGoogle Scholar
• TRUBESTEIN G, BALZER K, BISLER H: Buflomedil in arterial occlusive disease: results of a controlled multicentre study. Angiology (1984) 35:500-505.
   PubMed Web of Science ®Google Scholar
• DIAMANTOPOULOS EJ, GRIGORIADOU M, IFANTI G, RAPTY SA: Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Int. Angiol. (2001) 20:337-344.
   PubMedGoogle Scholar
• BREVETTI G, PERNA S, SABBA C, MARTONE VD, CONDORELLI M: Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J. Am. Coll. Cardiol. (1995) 26:1411-1416.
   PubMed Web of Science ®Google Scholar
• BREVETTI G, DIEHM C, LAMBERT D: European multicenter study on propionyl-L-carnitine in intermittent claudication. J. Am. Coll. Cardiol. (1999) 34:1618-1924.
   PubMed Web of Science ®Google Scholar
• BREVETTI G, PERNA S, SABBA C et al.: Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur. Heart J. (1992) 13:251-255.
   PubMed Web of Science ®Google Scholar
• BELCH JJF, BELL PRF, CREISSEN D et al.: Randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug in patients with intermittent claudication. Circulation (1997) 95:2298-2302.
   PubMed Web of Science ®Google Scholar
• LIEVRE M, AZOULY S, LION L, MORAND S, GIRRE JP, BOISSEL JP: A dose effect study of beraprost sodium in intermittent claudication. J. Cardiovasc. Pharmacol. (1996) 27:788-793.
   PubMed Web of Science ®Google Scholar
• LIEVRE M, MORAND S, BESSE B, FIESSINGER JN, BOISSEL JP: Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomised, multicenter controlled trial. Circulation (2000) 102:426-431.
   PubMed Web of Science ®Google Scholar
• REMIJNSE-TAMERIUS HC, DUPREZ D, DE BUYZERE M, OESEBURG B, CLEMENT DL: Why is training effective in the treatment of patients with intermittent claudication? Int. Angiol. (1999) 18:103-112.
   PubMed Web of Science ®Google Scholar
• DUPREZ D, DE BACKER TL, DE BUYZERE M, CLEMENT DL: Estimation of walking distance in intermittent claudication: need for standardization. Eur. Heart J. (1999) 20:641-644.
   PubMedGoogle Scholar
• SCATENA R, BOTTONI P, MARTORANA GE, GIARDINA B: Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert. Opin. Investig. Drugs (2005) 14:835-846.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TARDIF J-C, NICHOLLS SJ et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. (2007) 356:1304-1316.
   PubMed Web of Science ®Google Scholar
• KASTELEIN JJ, VAN LEUVEN SI, BURGESS L et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. (2007) 26 [Epub. ahead of print].
   Google Scholar
• Tall AR: CETP inhibitors to increase HDL cholesterol levels. N. Engl. J. Med. (2007) 356:1364-1366.
   PubMed Web of Science ®Google Scholar
• TUCCI SA, HALFORD JC, HARROLD JA, KIRKHAM TC: Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr. Med. Chem. (2006) 13:2669-2680.
   PubMed Web of Science ®Google Scholar